Para citar este trabalho use um dos padrões abaixo:
Introduction: Multiple Sclerosis (MS) is a chronic autoimmune disease of the central nervous system, characterized by demyelinating lesions caused by autoreactive lymphocytes that cross the blood-brain barrier (BBB) and promote neuroinflammation. Gut microbiota dysbiosis has been implicated in MS pathophysiology via gut-brain axis signaling. Lipopolysaccharide (LPS), a bacterial product from gram-negative microbiota, activates Toll-like receptor 4 (TLR4), promoting inflammatory responses linked to BBB dysfunction and neuroinflammation. Natalizumab (NTZ), a monoclonal antibody that blocks immune cell migration across the BBB, is highly effective, but approximately 25% of patients show inadequate response. Genetic variation in TLR4 may contribute to this interindividual variability. Objectives: To investigate the contribution of TLR4 genetic variants and TLR4-mediated inflammatory signaling to the therapeutic response to natalizumab in multiple sclerosis. Methods: We enrolled 139 NTZ-treated patients from HUPE-UERJ and HUCFF-UFRJ. Peripheral blood was collected for DNA extraction and SNP genotyping (rs10759931, rs2737190). PBMCs from genotyped healthy individuals were isolated, stimulated with LPS for 24h, and TLR4 expression was evaluated by qPCR. An EAE model is being standardized to further investigate TLR4 signaling and gut-brain axis mechanisms in NTZ response. Results: The polymorphic AA genotype of rs10759931 and rs2737190 was associated with better NTZ response, while the wild-type GG genotype prevailed among non-responders. In the functional assay, the GG genotype of rs10759931 was associated with higher TLR4 expression after LPS stimulation. Conclusion: TLR4 polymorphisms may influence NTZ efficacy in MS by modulating inflammatory signaling, supporting the relevance of pharmacogenetic mechanisms for personalized medicine strategies in MS. Financial Support: FAPERJ and CNPq. CAAE: 64171122.7.0000.5259/69411517.2.0000.5258. CEUA: 029/2025.
Com ~200 mil publicações revisadas por pesquisadores do mundo todo, o Galoá impulsiona cientistas na descoberta de pesquisas de ponta por meio de nossa plataforma indexada.
Confira nossos produtos e como podemos ajudá-lo a dar mais alcance para sua pesquisa:
Esse proceedings é identificado por um DOI , para usar em citações ou referências bibliográficas. Atenção: este não é um DOI para o jornal e, como tal, não pode ser usado em Lattes para identificar um trabalho específico.
Verifique o link "Como citar" na página do trabalho, para ver como citar corretamente o artigo